---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-001000"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T01:02:13.723361+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Bioworks expects to meet 2023 revenue guidance of $250-260M; cash nearly $950M

## Summary
- Preliminary cell engineering revenue $145-150M, biosecurity up to $110M, total revenue $250-260M.
- New Cell Programs added expected within 80-85 range, meeting prior guidance.
- Biopharma partnerships with Pfizer, Novo Nordisk, Merck, Boehringer Ingelheim; aggregate potential over $1.2B milestones.
- Ended 2023 with nearly $950M cash and cash equivalents; strong balance sheet.
- Full year 2023 financial results to be reported in February 2024.

## SEC filing metadata
- accession: 0001628280-24-001000
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/0001628280-24-001000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/dna-20240110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-001000
- JSON: https://secwatch.observer/filing/0001628280-24-001000.json
- Plain text: https://secwatch.observer/filing/0001628280-24-001000.txt

## Key facts
- Earnings Releases
  Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).
  - Period: for the year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Ginkgo continues to expect Total revenue of $250 – $260 million in 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/0001628280-24-001000-index.htm
- Earnings Releases
  Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).
  - Period: for the year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Preliminary unaudited Cell Engineering revenue is expected to be within the previously disclosed guidance range of $145 – $150 million in 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/0001628280-24-001000-index.htm
- Earnings Releases
  Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).
  - Period: for the year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Preliminary unaudited Biosecurity revenue is expected to be in line with the previously disclosed guidance of up to $110 million in 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/0001628280-24-001000-index.htm
- Earnings Releases
  Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).
  - Period: for the year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: New Cell Programs are expected to be within the previously disclosed guidance range of 80-85 new Cell Programs added to the platform in 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/0001628280-24-001000-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.